AiVF, a Tel Aviv, Israel-based medical technology company, raised $25m in Series A funding.
The round was led by Insight Partners with participation from Adam Neumann’s Family Office, 166 2nd.
The company will use the funding to accelerate adoption of its AI platform, EMA™ in the United States and Europe, expand its workforce and develop additional solutions to drive a new generation of digital fertility care.
Led by Daniella Gilboa, co-founder, CEO, and clinical embryologist, and Prof. Daniel Seidman, co-founder, chief medical officer, and an internationally renowned IVF specialist, AiVF develops an operational AI-based software platform, which provides an optimized end-to-end IVF journey to individuals seeking Assisted Reproductive Technologies for their family building. The advanced machine learning and computer vision algorithms have the potential to shorten the time to pregnancy and increase IVF predictability and success rates.
After three years of extensive research and development, the platform is now operational across Europe and Asia. AiVF anticipates rapid deployment of its platform, as fertility clinics look to incorporate second generation IVF technologies to allow for improved IVF care.